Reaktionsgleichung
[CH3:1][O:2][C:3]1[CH:29]=[CH:28][C:6]2[NH:7][C:8](=[O:27])[N:9]([CH:12]3[CH2:17][CH2:16][N:15]([C:18]4[CH:23]=[C:22]([C:24]([OH:26])=O)C=C[N:19]=4)[CH2:14][CH2:13]3)[CH2:10][CH2:11][C:5]=2[CH:4]=1.[NH2:30][C:31]1[CH:39]=[CH:38][CH:37]=[C:36]2[C:32]=1[CH:33]=[N:34][NH:35]2.[CH3:40][N:41](C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F>CN(C=O)C>[NH:35]1[C:36]2[C:32](=[C:31]([NH:30][C:24]([C:22]3[CH:23]=[C:18]([N:15]4[CH2:16][CH2:17][CH:12]([N:9]5[CH2:10][CH2:11][C:5]6[CH:4]=[C:3]([O:2][CH3:1])[CH:29]=[CH:28][C:6]=6[NH:7][C:8]5=[O:27])[CH2:13][CH2:14]4)[N:19]=[CH:40][N:41]=3)=[O:26])[CH:39]=[CH:38][CH:37]=2)[CH:33]=[N:34]1Komponenten
5
Edukt 3
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
100 mg (0.25 mmol) 4-(7-methoxy-2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-3,4,5,6-tetrahydro-2H-[1,2′]bipyridinyl-4′-carboxylic acid and 34 mg (0.25 mmol) 4-amino-indazole in 74 mμL (0.53 mmol) TEA and 1.5 mL DMF were combined with 89 mg (0.28 mmol) TBTU and the mixture was stirred overnight at RT. Then the reaction mixture was purified by preparative HPLC-MS. The product-containing fractions were combined and freeze-dried.
Aufarbeitung
- customThen the reaction mixture was purified by preparative HPLC-MS
- customfreeze-dried
Quellen und Nachweise
- ORD-Eintrag
- ord-2832dc2c146b469cb93d3bc6b833b7f1
- Quelldatensatz
- uspto-grants-2014_09
- Patentnummer
- US08829006B2
Verknüpfte Notizen
Wird geladen…